Meet In CommonNews

Local

Winners and losers of the trade deadline

Meet in Common connects news with real conversations. Use ThinkMatch to arrange a Roundtable and meet people to discuss this story.

Source: Victoria Advocate

The NFL has become an event-driven league. Long gone are the days when the season was just the season. Now it’s a year-round schedule of things that somehow become major talking points like the draft, the schedule reveal, and the annual “Will Aaron Rodgers finally retire?” stake-out. The latest one is the mid-season trade deadline, where we spend weeks arguing about which teams are going to go all-in on this season, and who needs to give up and settle for draft picks. Like every NFL interaction, we can always pick winners and losers from Tuesday’s trade deadline. Loser: The Cowboys. Dallas did nothing to improve their roster. Winner: Also the Cowboys, because neither did anyone else in that division. The Eagles have sold this season out for draft picks and Washington didn’t improve, but the Giants tried to get a big name running back and whiffed. No offense to Cam Skattebo, of course, the league loves a Gronkowski type who hits things with his head and gets injured a lot.

This excerpt comes from the named source. Read the original for the full reporting.

Read the original at Victoria Advocate

Featured places to meet in Palo Alto, CA

Explore these places and arrange a conversation through ThinkMatch.

Yutori

Yutori 3375 El Camino Real Palo Alto, CA, 94306 US

Cafe Riace

Cafe Riace 200 Sheridan Avenue Palo Alto, CA, US

City guide for Palo Alto, CA

Community Poll

A tradition can remain authentic while changing with the community that practices it.

Share your view, then see how readers voted. No sign-in required. This poll is shared across stories.

Do you agree or disagree?

Choose one answer

Common Quandary

A Common Quandary to discuss

Another conversation to explore, separate from this news story.

Would you want a doctor to give you a fake pill if the lie might make you feel better?

A patient has persistent symptoms that have not responded to standard treatments. A harmless placebo may help, but its effect could weaken if the clinician fully explains that it contains no active medicine.

Can a beneficial deception respect the person it helps?

Explore this quandary